Bridgeway Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Bridgeway Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-79,000	Closed	-$867K	–	1389
2020 Q1	$867K	Buy	79,000 +44,000	+126%	+$413K	0.02%	599
2019 Q4	$307K	Hold	35,000	–	–	﹤0.01%	1113
2019 Q3	$261K	Hold	35,000	–	–	﹤0.01%	1128
2019 Q2	$326K	Buy	+35,000	New	+$255K	﹤0.01%	1079
2018 Q4	–	Sell	-101,800	Closed	-$823K	–	1449
2018 Q3	$823K	Buy	101,800 +51,300	+102%	+$366K	0.01%	979
2018 Q2	$355K	Hold	50,500	–	–	﹤0.01%	1218
2018 Q1	$719K	Hold	50,500	–	–	0.01%	959
2017 Q4	$442K	Hold	50,500	–	–	﹤0.01%	1131
2017 Q3	$591K	Hold	50,500	–	–	0.01%	1045
2017 Q2	$705K	Hold	50,500	–	–	0.01%	964
2017 Q1	$693K	Buy	+50,500	New	+$524K	0.01%	947

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bridgeway Capital Management's SNDX Position: Q2 2020 in Review

Bridgeway Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2020, closing a stake of 79,000 shares — an estimated $867K sold.

Bridgeway Capital Management first reported a position in SNDX in Q1 2017 and held it in 11 quarters. The position peaked at $867K in Q1 2020. 97 funds tracked by Wall St. Rank hold SNDX as of Q2 2020.

Bridgeway Capital Management reported no remaining Syndax Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Bridgeway Capital Management sold 79,000 Syndax Pharmaceuticals shares in Q2 2020, an estimated $867K.
Bridgeway Capital Management first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 11 quarters.
Bridgeway Capital Management's Syndax Pharmaceuticals position peaked at $867K in Q1 2020.
97 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2020.

Based on Bridgeway Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.